Illumina Launches New Reagent Kits for the MiSeq® System Latest Milestone Doubles Sequencing Output to 15Gb, Enables Applications Including Exome Sequencing Business Wire SAN DIEGO -- August 19, 2013 Illumina, Inc. (NASDAQ:ILMN) today announced the availability of its newest reagent kits for the MiSeq, the industry’s most accurate and easiest-to-use benchtop sequencer. The improved chemistry doubles sequencing output to 15 gigabases (Gb) by increasing the number of sequencing reads (up to 25 million reads) and overall read length (up to 2x300 base pairs). These innovations enable researchers to perform new applications including exome sequencing on the MiSeq. In addition, increased sequencing reads will support transcriptome applications such as mRNA sequencing and will offer higher throughput capacity for gene expression profiling with Illumina’s TruSeq Targeted RNA Expression assay. The benefits of increased paired-end read lengths include improving the quality of genome assemblies and advancing applications that require longer read lengths, such as metagenomics and human leukocyte antigen (HLA) typing. “The new MiSeq kits are another example of how we are focused on continually improving the performance and value of our sequencing platforms for our customers,” said Christian Henry, Senior Vice President and General Manager of Illumina’s Genomic Solutions business. “The latest MiSeq system enhancements deliver the highest data quality and will open up new applications for researchers in markets as diverse as cancer, genetic disease, microbiology, agriculture and forensics.” Added Dr. Ellen Heitzer of the Institute for Human Genetics, Medical University of Graz in Austria, “As a beta customer, we have seen even more robust MiSeq performance with the new chemistry, including the ability to pool more samples for our circulating tumor assay. We’ve also seen excellent sequencing quality, with almost 90 percent of clusters passing the filter and 96 percent of reads with a quality score greater than 30. In addition, the longer read length will facilitate the identification of translocations and fusion genes for our target resequencing approaches." The new MiSeq reagent kits are now shipping, including a 600-cycle kit and a 150-cycle kit. For more information visit, www.illumina.com/MiSeq. About Illumina Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare. Forward-Looking Statements This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release. Contact: Illumina, Inc. Investors: Rebecca Chambers 858-255-5243 firstname.lastname@example.org or Media: Jennifer Temple 858-882-6822 email@example.com
Illumina Launches New Reagent Kits for the MiSeq® System
Press spacebar to pause and continue. Press esc to stop.